Table of contents

  • Brand Names
  • Chemistry
  • Pharmacologic Category
  • Mechanism of Action
  • Therapeutic Use
  • Pregnancy and Lactation Implications
  • Contraindications
  • Warnings and Precautions
  • Adverse Reactions
  • Genes that may be involved
  • Drug Interactions
  • Nutrition/Nutraceutical Interactions
  • Dosage
  • Pharmacokinetics and Pharmacodynamics
  • Special Considerations

Brand Names

North America

USA: Symlin.

Drug combinations


Pramlintide Acetate: C~171~H~267~N~51~O~53~S~2~ xC~2~H~4~O~2~ yH~2~O. Mw: 3949.40. (1) 25-L-Proline-28-L-proline-29-L-prolineamylin (human) acetate, hydrate; (2) L-Lysyl-L-cysteinyl-L-asparaginyl-L-threonyl-L-alanyl-L-threonyl-L-cysteinyl-L-alanyl-L-threonyl-L-glutaminyl-L-arginyl-L-leucyl-L-alanyl-L-asparaginyl-L-phenylalanyl-L-leucyl-L-valyl-L-histidyl-L-seryl-L-seryl-L-asparaginyl-L-asparaginyl-L-phenylalanylglycyl-L-prolyl-L-isoleucyl-L-leucyl-L-prolyl-L-prolyl-L-threonyl-L-asparaginyl-L-valylglycyl-L-seryl-L-asparaginyl-L-threonyl-L-tyrosinamide, cyclic (2→7)-disulfide, acetate, hydrate. CAS-196078-30-5 (1997).

Pharmacologic Category

Antidiabetic Agents; Amylinomimetics. (ATC-Code: A10BX05).

Mechanism of action

Reduces postprandial glucose increases via prolongation of gastric emptying time, reduction of postprandial glucagon secretion, and reduction of caloric intake through centrally-mediated appetite suppression.

Therapeutic use

Adjunctive treatment with mealtime insulin in type 1 diabetes mellitus (insulin-dependent). Adjunctive treatment with mealtime insulin in type 2 diabetes mellitus (non-insulin-dependent).

Pregnancy and lactiation implications

Caution during lactation.

Unlabeled use


Hypersensitivity to pramlintide or any component of the formulation. Confirmed diagnosis of gastroparesis. Hypoglycemia unawareness.

Warnings and precautions

Avoid use in conditions or concurrent medications likely to impair gastric motility (e.g. anticholinergics). Do not use in patients requiring medication(s) to stimulate gastric emptying. Use with caution in history of nausea, and in neuropathic conditions which may mask signs/symptoms of hypoglycemia. Use caution with certain antihypertensive agents (e.g. β-adrenergic blockers) which may mask signs/symptoms of hypoglycemia. Co-administration with insulin may induce severe hypoglycemia (usually within 3 hours following administration). Concurrent use of other glucose-lowering agents may increase risk of hypoglycemia. Do not use in HgbA~1c~ levels >9% or recent, recurrent episodes of hypoglycemia. Use caution in visual or dexterity impairment.



Legal Notice
Privacy Policy
Cookie Policy


Phone: +34-981-780505
Location: Sta Marta de, C. P. Babío, S/N, 15165 Bergondo, A Coruña

Copyright © 2023 WAGEM

Add to cart